On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...

GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Millions of Americans would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare ...

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...

If the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...